Related Experiment Videos
Review article: balsalazide therapy in ulcerative colitis
1Centre for Digestive Diseases and Nutrition, Morriston Hospital, Swansea SA6 6NL, UK. ragunath@doctors.org.uk
Alimentary Pharmacology & Therapeutics
|September 21, 2001
Summary
Balsalazide, a 5-aminosalicylic acid pro-drug, effectively treats ulcerative colitis with fewer side effects than sulfasalazine. It demonstrates superior patient tolerability and efficacy in achieving remission, particularly for left-sided disease.
Area of Science:
- Gastroenterology
- Pharmacology
- Inflammatory Bowel Disease Research
Background:
- Balsalazide is a pro-drug of 5-aminosalicylic acid (mesalazine), utilizing an inert carrier molecule.
- It is engineered to deliver mesalazine to the colonic mucosa, bypassing the sulfapyridine moiety associated with sulfasalazine.
- This formulation aims to mitigate sulfasalazine-related side effects while maintaining therapeutic efficacy.
Purpose of the Study:
- To evaluate the efficacy and patient tolerance of balsalazide in treating ulcerative colitis.
- To compare balsalazide's effectiveness against mesalazine and sulfasalazine in inducing and maintaining remission.
- To assess balsalazide's benefit in specific patient subgroups, including those with left-sided disease and nocturnal symptoms.
Main Methods:
- Review of several studies investigating balsalazide's clinical outcomes.
- Comparative analysis of balsalazide versus mesalazine at equivalent doses for acute ulcerative colitis.
- Assessment of balsalazide's efficacy in maintaining remission compared to sulfasalazine and mesalazine.
Main Results:
- Balsalazide induced symptomatic and complete remission in a greater proportion of patients compared to mesalazine.
- Patients with resistant left-sided ulcerative colitis showed a higher probability of achieving remission with balsalazide.
- Balsalazide demonstrated significant benefits for patients experiencing nocturnal symptoms and exhibited superior tolerability with minimal side effects.
Conclusions:
- Balsalazide is an effective treatment for ulcerative colitis, offering comparable remission maintenance to sulfasalazine and mesalazine.
- Its primary advantage lies in superior patient tolerability, making it a favorable alternative to other 5-aminosalicylic acid compounds.
- Balsalazide represents a valuable therapeutic option for managing ulcerative colitis, especially in patients sensitive to sulfasalazine side effects.